Japan to See Arrival of 1st Treatment for HFpEF, Will Entresto Meet Unmet Medical Needs?
To read the full story
Related Article
- Hypertension OK Now in Hand, Novartis Expanding Entresto Pitch to GPs with Superior Efficacy over ARBs
November 1, 2021
- Personalized Approach Needed for HFpEF Treatment with Entresto: Professor
August 28, 2020
- As Entresto Hits Japan Market, Novartis Poised to Tap All Channels to Push Global Blockbuster
August 26, 2020
- Japan Approves Entresto, 4 Other Novartis Meds, Rybelsus, 1st Humira Biosimilar and More
June 30, 2020
- Eyes Turn to SGLT2 Inhibitors after Entresto’s Narrow Miss in HFpEF
October 16, 2019
COMMENTARY
- How Will Japan Deal with Expected Cost Spike with Japan-Made Antibiotic APIs?
April 1, 2025
- Fair or Unfair? PMP Return Applied for First Time in Off-Year Revision
March 24, 2025
- Evolving GLP-1 Drugs: Could Double and Triple Agonists Achieve Blockbuster Status?
March 4, 2025
- New Govt Fund for Innovative Drugs: Twists, Turns, and Hope
February 10, 2025
- Companies Welcome Generic Drug Fund, but Fret Pricing and Regulations
February 5, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…